• This record comes from PubMed

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

. 2021 Apr 08 ; 384 (14) : 1289-1300. [epub] 20210213

Language English Country United States Media print-electronic

Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Grant support
P30 CA008748 NCI NIH HHS - United States

BACKGROUND: Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. RESULTS: A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P<0.001) and was longer with lenvatinib plus everolimus than with sunitinib (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P<0.001). Overall survival was longer with lenvatinib plus pembrolizumab than with sunitinib (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) but was not longer with lenvatinib plus everolimus than with sunitinib (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received lenvatinib plus pembrolizumab, 83.1% of those who received lenvatinib plus everolimus, and 71.8% of those who received sunitinib. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels. CONCLUSIONS: Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

. 2025 May 27 ; 74 (7) : 225. [epub] 20250527

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

. 2025 May 09 ; 74 (7) : 196. [epub] 20250509

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

. 2025 Apr 01 ; 156 (7) : 1326-1335. [epub] 20241230

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

. 2025 Jan 03 ; 74 (2) : 65. [epub] 20250103

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

. 2024 Nov ; 19 (6) : 893-903. [epub] 20240917

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

. 2024 Jun 04 ; 73 (8) : 142. [epub] 20240604

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

. 2024 Apr 10 ; 42 (11) : 1222-1228. [epub] 20240116

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

. 2024 Apr ; 41 (2) : 117-129. [epub] 20240216

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

. 2024 Mar ; 19 (2) : 175-180. [epub] 20240203

Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data

. 2024 Jan 30 ; 73 (2) : 38. [epub] 20240130

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma

. 2023 Nov ; 18 (6) : 893-903. [epub] 20231113

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

. 2023 ; 13 () : 1223282. [epub] 20230816

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

. 2023 Aug ; 6 (4) : 437-446. [epub] 20230129

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

. 2023 Jul 29 ; 15 (15) : . [epub] 20230729

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

. 2023 Jul ; 18 (4) : 559-570. [epub] 20230627

Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis

. 2023 Jul ; 41 (7) : 1763-1774. [epub] 20230520

Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma

. 2023 Jan-Feb ; 37 (1) : 393-399.

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis

. 2022 ; 12 () : 946307. [epub] 20220802

Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis

. 2022 Jun ; 7 (3) : 100474. [epub] 20220513

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines

. 2021 Aug ; 6 (4) : 100122. [epub] 20210701

See more in PubMed

ClinicalTrials.gov
NCT02811861

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...